GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Diamyd Medical DMYD B.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

0.98

+0.61%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Diamyd Medical

Its shares trade on Nasdaq Stockholm under the ticker DMYD B.ST. It has been listed since 20 May 2013. In the fiscal year to 31 August 2025, it reported revenue of SEK 130,000 and a net loss of SEK 169.8m. At that date it held total assets of SEK 352.6m and shareholders' equity of SEK 280.0m.

Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2013-05-20. The company is active in the field of pharmaceutical development and investments in stem cell and medical technology. The firm develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
20 May 2013
Employees
7
Website
diamyd.com ↗

Leadership

Pay as last reported

  • Mr. Anders EssenmoellerIndependent Non-Executive Chairman of the Board, since 2013SEK 1.1m
  • Mr. Ulf HanneliusChief Executive OfficerSEK 3.4m
  • Mr. Erik NerpinIndependent Non-Executive Vice Chairman of the BoardSEK 214,000
  • Ms. Anna StyrudChief Financial Officer
  • Ms. Martina WidmanChief Operating Officer
  • Mr. Anton LindqvistChief Scientific Officer
  • Dr. Maja JohanssonChief Operating Officer - Manufacturing
  • Ms. Maria-Teresa Essen-MoellerDirectorSEK 164,000
  • Prof. Dr. Mark AtkinsonIndependent DirectorSEK 175,000
  • Prof. Torbjoern BaeckstroemIndependent DirectorSEK 138,000
  • Dr. Karin HehenbergerIndependent DirectorSEK 125,000
  • Dr. Karin RosenIndependent DirectorSEK 125,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
19
Environment
19
Social
33
Governance
6
Women in the workforce
62.96%
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Diamyd Medical AB possesses several strengths that contribute to its success:

Weaknesses

  • Despite its strengths, Diamyd Medical AB also encounters some weaknesses:

Opportunities

  • Diamyd Medical AB can leverage the following opportunities to further grow its business:

Threats

  • It is important for Diamyd Medical AB to be aware of and address the following threats:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.